Cancer Drug Aces Its Tests

All Access winner CBS/The Early Show

Millennium Pharmaceuticals Inc. plans to end late-stage trials of blood cancer drug Velcade early because the drug had proven effective. Its shares rose more than 4 percent in early trading.

Cambridge-based Millennium said Monday the decision would enable patients being treated with another drug in the trial to switch over to Velcade.

Millenium said it would share data from the study at a medical conference during the first half of next year, after originally planning to release the information in 2005.

Millennium said patients suffering from multiple myeloma, a cancer of the blood, who received Velcade showed a "statistically significant improvement" compared to those receiving high-dose dexamethasone. The decision allows dexamethasone patients in the trial to switch over to Velcade.

Millennium is developing the drug with Johnson & Johnson Pharmaceutical Research & Development L.L.C.

Federal regulators gave Velcade an expedited approval last May based on a smaller trial.


Watch CBSN Live

Watch CBS News anytime, anywhere with the new 24/7 digital news network. Stream CBSN live or on demand for FREE on your TV, computer, tablet, or smartphone.

Watch Now

New Android App

For your Android phone and tablet, download the FREE redesigned app, featuring CBSN, live 24/7 news.

The all new
CBS News App for Android® for iPad® for iPhone®
Fully redesigned. Featuring CBSN, 24/7 live news. Get the App